Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
March 20, 2026

Congruence secures $39.5m to advance small molecule correctors pipeline

Congruence Therapeutics has announced the completion of a $39.5m financing round to advance its portfolio of small molecule correctors into the clinic.

Congruence aims to submit CTA/IND applications for the programmes in early 2027. Credit: Minerva Studio / Shutterstock.com.